Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

Teaching tape for the motor section of the unified Parkinson's disease rating scale.

Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD.

Mov Disord. 1995 May;10(3):263-6.

PMID:
7544438
2.

Cerebrospinal fluid from patients with Parkinson's disease alters the survival of dopamine neurons in mesencephalic culture.

Yu SJ, Lo ES, Cochran EJ, Lin DH, Faselis CJ, Klawans HL, Carvey PM.

Exp Neurol. 1994 Mar;126(1):15-24.

PMID:
7908885
3.
4.

Fetal-tissue transplantation for Parkinson's disease.

Goetz CG, Penn RD, Klawans HL.

N Engl J Med. 1993 Nov 11;329(20):1498; author reply 1499-500. No abstract available.

PMID:
8413464
5.

Medicine's Last Commandment.

Klawans HL.

Med Econ. 1993 May 24;70(10):104-7, 111. No abstract available.

PMID:
10126055
6.

Striatal extracts from patients with Parkinson's disease promote dopamine neuron growth in mesencephalic cultures.

Carvey PM, Ptak LR, Nath ST, Sierens DK, Mufson EJ, Goetz CG, Klawans HL.

Exp Neurol. 1993 Mar;120(1):149-52.

PMID:
8097475
7.

Chorea in childhood.

Klawans HL, Brandabur MM.

Pediatr Ann. 1993 Jan;22(1):41-6, 49-50. Review. No abstract available.

PMID:
8094241
8.

Synaptic plasticity in the rat striatum following chronic haloperidol treatment.

Kerns JM, Sierens DK, Kao LC, Klawans HL, Carvey PM.

Clin Neuropharmacol. 1992 Dec;15(6):488-500.

PMID:
1335837
9.

Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease.

Diederich N, Goetz CG, Stebbins GT, Klawans HL, Nittner K, Koulosakis A, Sanker P, Sturm V.

Neurology. 1992 Jul;42(7):1311-4.

PMID:
1620340
10.

United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up.

Goetz CG, Stebbins GT 3rd, Klawans HL, Koller WC, Grossman RG, Bakay RA, Penn RD.

Neurology. 1991 Nov;41(11):1719-22.

PMID:
1944898
11.

Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures.

Carvey PM, Ptak LR, Lo ES, Lin DH, Buhrfiend CM, Goetz CG, Klawans HL.

Exp Neurol. 1991 Oct;114(1):28-34.

PMID:
1915732
12.

The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease.

Carvey PM, McRae A, Lint TF, Ptak LR, Lo ES, Goetz CG, Klawans HL.

Neurology. 1991 May;41(5 Suppl 2):53-8; discussion 59-60. Review.

PMID:
2041594
13.

Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin A or basic fibroblast growth factor in ventricular fluid.

Shults CW, O'Connor DT, Baird A, Hill R, Goetz CG, Watts RL, Klawans HL, Carvey PM, Bakay RA, Gage FH, et al.

Exp Neurol. 1991 Mar;111(3):276-81.

PMID:
1999231
14.

Dopamine distribution and behavioral alterations resulting from dopamine infusion into the brain of the lesioned rat.

Kroin JS, Kao LC, Zhang TJ, Penn RD, Klawans HL, Carvey PM.

J Neurosurg. 1991 Jan;74(1):105-11.

PMID:
1984488
15.

Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results.

Olanow CW, Koller W, Goetz CG, Stebbins GT, Cahill DW, Gauger LL, Morantz R, Penn RD, Tanner CM, Klawans HL, et al.

Arch Neurol. 1990 Dec;47(12):1286-9.

PMID:
2252446
16.

Clozapine fails to prevent the development of haloperidol-induced behavioral hypersensitivity in a cotreatment paradigm.

Carvey PM, Nath ST, Kao LC, Zhang TJ, Lin DH, Singh R, Amdur RL, Klawans HL.

Eur J Pharmacol. 1990 Aug 2;184(1):43-53.

PMID:
2209714
17.

Convulsive disorders: mechanisms of epilepsy and anticonvulsant action.

Bleck TP, Klawans HL.

Clin Neuropharmacol. 1990 Apr;13(2):121-8. Review. No abstract available.

PMID:
2183933
18.

Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity.

Carvey PM, Kao LC, Zhang TJ, Amdur RL, Lin DH, Singh R, Klawans HL.

Pharmacol Biochem Behav. 1990 Feb;35(2):291-300.

PMID:
2320636
19.

Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data.

Goetz CG, Tanner CM, Penn RD, Stebbins GT 3rd, Gilley DW, Shannon KM, Klawans HL, Comella CL, Wilson RS, Witt T.

Neurology. 1990 Feb;40(2):273-6.

PMID:
2300248
20.

Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor.

Carvey PM, McRae A, Ptak LR, Kao LC, Lo ES, Goetz CG, Tanner CM, Penn RD, Klawans HL.

Prog Brain Res. 1990;82:693-7. No abstract available.

PMID:
2290972
21.

United Parkinson Foundation Neurotransplantation Registry: multicenter US and Canadian data base, presurgical and 12 month follow-up.

Goetz CG, Stebbins GT 3rd, Klawans HL, Koller WC, Grossman RG, Bakay RA, Penn RD.

Prog Brain Res. 1990;82:611-7. No abstract available.

PMID:
2290962
22.

L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia.

Goety CG, Tanner CM, Cohen JA, Thelen JA, Carroll VS, Klawans HL, Fariello RG.

Mov Disord. 1990;5(3):263-5. No abstract available.

PMID:
2143808
23.

Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.

Goetz CG, Tanner CM, Gilley DW, Klawans HL.

Neurology. 1989 Nov;39(11 Suppl 2):63-6; discussion 72-3.

PMID:
2586764
24.
25.

Hypersexuality with antiparkinsonian therapy.

Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B.

Clin Neuropharmacol. 1989 Oct;12(5):375-83.

PMID:
2575449
26.

Agonist substitution in advanced Parkinson's disease.

Goetz CG, Shannon KM, Tanner CM, Carroll VS, Klawans HL.

Neurology. 1989 Aug;39(8):1121-2.

PMID:
2761708
27.

Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease.

Goetz CG, Olanow CW, Koller WC, Penn RD, Cahill D, Morantz R, Stebbins G, Tanner CM, Klawans HL, Shannon KM.

N Engl J Med. 1989 Feb 9;320(6):337-41.

PMID:
2643770
28.

An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantation.

McRae-Degueurce A, Klawans HL, Penn RD, Dahlstrom A, Tanner CM, Goetz CG, Carvey PM.

Neurosci Lett. 1988 Nov 22;94(1-2):192-7.

PMID:
3241668
29.

Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.

Goetz CG, Tanner CM, Shannon KM, Carroll VS, Klawans HL, Carvey PM, Gilley D.

Neurology. 1988 Jul;38(7):1143-6.

PMID:
3290706
30.

The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients.

Penn RD, Goetz CG, Tanner CM, Klawans HL, Shannon KM, Comella CL, Witt TR.

Neurosurgery. 1988 Jun;22(6 Pt 1):999-1004.

PMID:
3419583
31.

Hemiparkinsonism with hemiatrophy.

Buchman AS, Goetz CG, Klawans HL.

Neurology. 1988 Apr;38(4):527-30.

PMID:
3352904
32.
33.

Cholinergic pharmacology of blepharospasm with oromandibular dystonia (Meige's syndrome).

Klawans HL, Tanner CM.

Adv Neurol. 1988;49:443-50. Review. No abstract available.

PMID:
3278551
34.

Psychiatric side effects during the treatment of Parkinson's disease.

Klawans HL.

J Neural Transm Suppl. 1988;27:117-22. Review.

PMID:
3042909
35.

Epidemiology and pathophysiology of tardive dyskinesias.

Klawans HL, Tanner CM, Goetz CG.

Adv Neurol. 1988;49:185-97. Review. No abstract available.

PMID:
2894124
36.

Amantadine and motor fluctuations in chronic Parkinson's disease.

Shannon KM, Goetz CG, Carroll VS, Tanner CM, Klawans HL.

Clin Neuropharmacol. 1987 Dec;10(6):522-6.

PMID:
3427558
37.

Controlled-release Sinemet.

Goetz CG, Tanner CM, Carroll VS, Shannon KM, Klawans HL.

Neurology. 1987 Sep;37(9):1567-8. No abstract available.

PMID:
3627466
38.

Chorea.

Klawans HL.

Can J Neurol Sci. 1987 Aug;14(3 Suppl):536-40. Review.

PMID:
2445458
39.

Effects of dopamine antagonists and apomorphine on regional energy metabolism in rat CNS.

Carvey PM, Braun AR, Kao LC, Klawans HL.

Clin Neuropharmacol. 1987 Jun;10(3):247-60.

PMID:
3454716
40.

Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).

Goetz CG, Tanner CM, Klawans HL, Shannon KM, Carroll VS.

Neurology. 1987 May;37(5):875-8.

PMID:
3574696
41.

The effect of bilateral kainic acid-induced lateral habenula lesions on dopamine-mediated behaviors.

Carvey PM, Kao LC, Klawans HL.

Brain Res. 1987 Apr 14;409(1):193-6.

PMID:
3580867
42.

Memory failure in Huntington's disease.

Wilson RS, Como PG, Garron DC, Klawans HL, Barr A, Klawans D.

J Clin Exp Neuropsychol. 1987 Apr;9(2):147-54.

PMID:
2951396
43.

Pergolide mesylate: four years experience in Parkinson's disease.

Tanner CM, Goetz CG, Glantz RH, Klawans HL.

Adv Neurol. 1987;45:547-9. No abstract available.

PMID:
3825732
44.

Depression and cognitive changes in Parkinson's disease: a review.

Bieliauskas LA, Klawans HL, Glantz RH.

Adv Neurol. 1987;45:437-8. No abstract available.

PMID:
3825722
45.

Metrizamide and its neurologic complications.

Buchman AS, Klawans HL, Russell EJ.

Clin Neuropharmacol. 1987;10(1):1-25. Review. No abstract available.

PMID:
3545458
46.
47.

Neurologic emergencies.

Bleck TP, Klawans HL.

Med Clin North Am. 1986 Sep;70(5):1167-84.

PMID:
3016427
48.

The effect of thioridazine on haloperidol induced behavioral hypersensitivity.

Klawans HL, Carvey PM, Nelson D, Tanner CM, Goetz CG.

Life Sci. 1986 May 12;38(19):1707-14.

PMID:
3702600
49.

Pharmacology of dementia.

Klawans HL, Genovese N.

Neurol Clin. 1986 May;4(2):459-67. Review.

PMID:
2872586
50.

The effect of antimuscarinic agents on haloperidol induced behavioral hypersensitivity.

Carvey PM, Kao LC, Tanner CM, Goetz CG, Klawans HL.

Eur J Pharmacol. 1986 Jan 21;120(2):193-9.

PMID:
3948919

Supplemental Content

Loading ...
Support Center